Alphabet, WuXi AppTec, Celgene, Roche and Novartis are in line to exit precision oncology therapy developer Ideaya Biosciences, which has filed to go public.

Cambridge Enterprise and CIC featured in cancer therapy developer PolyProx Therapeutics’ seed round, which will coommercialise research from the university’s pharmacology department.

MRCF has kickstarted a fifth fund to make early-stage investments in medical technologies from its network of member research institutions in Australia and New Zealand.

UCL bowel cancer diagnostics spinout Odin Vision has attracted the UCL Technology Fund in a round that will support trials of its first computer vision-powered product.

Bpifrance and HTGF are among the investors for Alentis Therapeutics’ series A round, proceeds of which will support the development of a therapy for liver fibrosis and cancer.

Spun out of University of Nantes and research institute Inserm, GoLiver Therapeutics hopes to catalyse a stem cell-based regenerative drug candidate for the treatment of acute and chronic severe liver failure.

Dicronis hopes its microneedle-based device will help clinicians catch impairments in cancer patients’ lymphatic network that cause chronic swelling in the legs, arm of chest.

Cambridge Innovation Capital is in line for an exit as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.

Astellas, Novartis and GlaxoSmithKline are in line for exits as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.

The drug developer has confidentially filed for an IPO having collected $124m in funding from investors including PureTech Health, Nan Fung and Alexandria Real Estate Equities.